Delayed clearance of serum HBsAG in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis

American Journal of Gastroenterology

Volumn 93, Issue 6, 1998, Pages 896-900

  Fattovich, Giovanna ^g   Giustina, Giuliano ^h   Sanchez Tapias, José ^h   Quero, Carlos ^h   Mas, Anna ^h   Olivotto, Pia Grazia ^h   Solinas, Antonio ^h   Almasio, Piero ^h   Hadziyannis, Stephanos ^h   Degos, Francoise ^h   De Moura, Miguel Carneiro ^h   Krogsgaard, Kim ^h   Pantalena, Maurizio ^h   Realdi, Giuseppe ^h   Corrocher, Roberto ^h   Schalm, Solko W ^h   Craxi A ^a   Delarocque, E ^b   Savvas, S ^c   Cossu, Pa ^d   Tocco, A ^d   Olsen, Jf ^h   Christensen, E ^e   Rocha, P ^f   more..

^a UNIVERSITY OF PALERMO   (Italy)

^b BEAUJON HOSPITAL   (France)

^c HIPPOKRATION HOSPITAL   (Greece)

^d UNIVERSITY OF SASSARI   (Italy)

^e BISPEBJERG HOSPITAL   (Denmark)

^f Medical School of Lisbon   (Portugal)

^g UNIVERSITY OF VERONA   (Italy)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; STEROID; VIDARABINE;

ADULT; ARTICLE; CANCER RISK; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0001731999     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00272.x     Document Type: Article

References (23)

1. 1. Sampliner RE, Hamilton FA, Iseri OA, et al. The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers. Am J Med Sci 1979;277:17-22.
2. 2. Viola LA, Barrison IG, Coleman JC, et al. Natural history of liver disease in chronic hepatitis B surface antigen carriers. Lancet 1981;2: 1156-9.
3. 3. Alward WLM, McMahon BJ, Hall DB, et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985;151:604-9.
4. 4. Poralla T, Manns M, Hutteroth TH, et al. HBsAg clearance in patients with long-standing chronic active hepatitis B and hepatitis B virus-induced liver cirrhosis. Digestion 1986;33:53-60.
5. 5. Morgan TR, Redeker AG, Yamada S, et al. HBsAg clearance in chronic active hepatitis B. Dig Dis Sci 1986;31:700-4.
6. 6. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study. J Hepatol 1994;21:656-66.
7. 7. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995;21:77-82.
8. 8. Infante-Rivard C, Villeneuve JP, Esnaola S. A framework for evaluating and conducting prognostic studies: An application to cirrhosis of the liver. J Clin Epidemiol 1989;42:791-805.
9. 9. Bianchi L, De Groote J, Desmet VJ, et al. Acute and chronic hepatitis revisited. Lancet 1977;2:914-9.
10. 10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
11. 11. Peto R, Pike MC. Conservation of the approximation (O-E)/E in the logrank test for survival data on tumor incidence data. Biometrics 1973;29:579-84.
12. 12. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-220.
13. 13. Rao CR. Linear statistical inference and its application. New York: Wiley, 1973.
14. 14. Beale EML, Little RJA. Missing values in multivariate analysis. J R Stat Soc 1975;37:129-45.
15. 15. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
16. 16. Niederau C, Heintges T, Lange S, et al. Long term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
17. 17. Lok ASF. Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma? Hepatology 1995;22:1336-8.
18. 18. Fattovich G, Tagger A, Brollo L, et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis 1991;163:400-2.
19. 19. Sheen IS, Liaw YF, Chu CM, et al. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis 1992;165:831-4.
20. 20. Colombo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in italian patients with cirrhosis. N Engl J Med 1991;325: 675-80.
21. 21. Chung HT, Lai CL, Lok ASF. Pathogenetic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995;22:25-9.
22. 22. De Jongh FE, Janssen HLA, De Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
23. 23. Fattovich G, Giustina G, Realdi G, et al. Long term outcome of HBeAg positive patients with compensated cirrhosis treated with interferon alpha. Hepatology 1997;26:1338-42.